Therefore, in this study, we aim to explore the recurrence and prognosis of resected stage III acral and cutaneous melanoma patients treated by PD-1 inhibitor, conventional interferon (IFN), or simple observation (OBS) and identify a subgroup of patients who might have benefited in one of the most prominent Chinese cancer centers. This evidence concerns the gene IFNA1 and cutaneous melanoma.